Advanced Angiosarcoma
Conditions
Keywords
angiosarcoma
Brief summary
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
Detailed description
TRC105 (carotuximab) is a monoclonal antibody to endoglin (CD105), an essential angiogenic target highly expressed on tumor vessels that is distinct from VEGFR. Endoglin is also expressed directly on tumor cells in angiosarcoma and is upregulated following VEGF inhibition. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models and complements the activity of bevacizumab and multi-kinase inhibitors that target the VEGFR. Pazopanib is an oral inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. By targeting a non-VEGF pathway that is upregulated following VEGF inhibition, TRC105 has the potential to complement VEGFR tyrosine kinase inhibitors (TKIs) and could represent a major advance in the treatment of angiosarcoma. Together, the use of TRC105 with pazopanib may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with pazopanib alone.
Interventions
BIOLOGICALTRC105
TRC105 antibody
DRUGVotrient
pazopanib
Sponsors
Tracon Pharmaceuticals Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically-confirmed angiosarcoma that is not amenable to curative intent surgery (e.g., metastatic or bulky disease and disease for which surgical resection would carry an unacceptable risk to the patient). Pathology report will be reviewed by sponsor prior to randomization. 2. Documented progression on or following most recent systemic chemotherapy regimen (not required for chemotherapy-naïve patients), within 4 months prior to screening 3. Measurable disease by RECIST v1.1 4. Age of 18 years or older; in addition, patients age 12 to 17 years may enroll beginning in Cohort 2 if weight ≥ 40 kg 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 6. Resolution of all acute AEs resulting from prior cancer therapies to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) grade ≤ 1 or to that patient's pre-study baseline (except alopecia or neuropathy) 7. Adequate organ function 8. Willingness and ability to consent (and assent if under age 18) for self to participate in study 9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 10. Angiosarcoma tumor specimen, if available 11. Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide (refer to Section 2.6.1.3) and to not donate sperm during the study and for at least 180 days following last dose of TRC105 or pazopanib 12. Woman of non-child bearing potential due to surgical sterilization (at least 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history or menopause (i.e., no menstrual bleeding for more than 12 months in a women aged 45 years or more), OR woman of child bearing potential who test negative for pregnancy at time of enrollment based on serum pregnancy test and agree to use at least 2 acceptable methods of birth control, one of which must be highly effective, during the study and for at least 180 days after stopping TRC105 or pazopanib
Exclusion criteria
1. Prior treatment with TRC105 2. Prior treatment with any VEGF inhibitor 3. More than two prior lines (may be combination regimens) of chemotherapy for angiosarcoma (neoadjuvant/adjuvant treatment does not count as a line of treatment) 4. Current treatment or participation on another therapeutic clinical trial 5. Women who are pregnant or breastfeeding 6. Receipt of systemic anticancer therapy, including investigational agents, within 5 times the agent's elimination half-life of starting study treatment 7. Major surgical procedure or significant traumatic injury within 4 weeks prior to randomization and must have fully recovered from any such procedure or injury; planned surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months. Note: the following are not considered to be major procedures and are permitted up to 7 days before randomization: Thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, and imaging-guided biopsy for diagnostic purposes 8. Patients who have received wide field radiotherapy ≤ 28 days (defined as \> 50% of volume of pelvic bones or equivalent) or limited field radiation for palliation \< 14 days prior to randomization 9. Uncontrolled hypertension defined as systolic \> 150 or diastolic \> 100 mm Hg on the average of the 3 most recent BP readings. Anti-hypertensives may be started prior to randomization. 10. Ascites or pleural effusion requiring intervention or that required intervention or recurred within three months prior to randomization 11. Pericardial effusion (except trace effusion identified by echocardiogram) within three months prior to randomization 12. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days prior to randomization 13. Angina, myocardial infarction, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism , pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) within 6 months prior to randomization. Deep venous thrombosis within 3 months prior to randomization unrelated to a central venous catheter, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks prior to randomization. In this situation, low molecular weight heparin is preferred 14. Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia). Patients with bleeding cutaneous lesions not actively requiring transfusions are eligible. Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible 15. Hemoptysis (\> ½ teaspoon \[2.5 mL\] of bright red blood) within 6 months prior to randomization 16. Thrombolytic use (except to maintain i.v. catheters) within 10 days prior to randomization 17. Known active viral or nonviral hepatitis or cirrhosis 18. Peptic ulcer within the past 3 months prior to randomization, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) 19. Presence of tumor(s) invading into the heart or great vessels (including carotid artery) or another location where bleeding is associated with high morbidity including patients with primary cardiac or great vessel angiosarcoma 20. Gastrointestinal perforation or fistula in the 6 months prior to randomization unless underlying risk has been resolved (e.g., through surgical resection or repair) 21. Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanib 22. History of prior malignancy except adequately treated basal cell or squamous cell skin cancer or adequately treated, with curative intent, cancer from which the patient is currently in complete remission per Investigator's judgment; patients with history of breast cancer and no evidence of disease on hormonal therapy to prevent recurrence and patients with prostate cancer on adjuvant hormonal therapy with undetectable PSA are eligible 23. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness 24. Active infection that requires systemic treatment 25. Concurrent use or receipt of a strong CYP3A4 inducer within 12 days prior to randomization or a strong CYP3A4 inhibitor within 7 days prior to randomization (see Table 10) 26. History of severe hypersensitivity reaction to any monoclonal antibody 27. Other severe acute or chronic medical (including bone marrow suppressive diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, impede the ability of the patient to complete all protocol-specified activities, or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival of Patients With Unresectable Angiosarcoma | from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months) | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression free survival is defined as time from randomization to either first disease progression (per independent radiology review of images by RECIST 1.1) or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate of Patients With Unresectable Angiosarcoma | from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months) | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Overall response rate is defined as the number of patients with a best response designation of complete response or partial response recorded between the date of randomization and the date of documented progression. |
| Overall Survival of Patients With Unresectable Angiosarcoma | from beginning of study to cut off date of interim analysis (25 months) | Overall survival is the number of death events at 25 months, including all on-study and off-study deaths (past post-treatment 28-day follow up visit) |
| To Characterize Patient Reported Outcomes Between the Two Arms of the Study | Screening and 9 weeks (Cycle 3 Day 1) | Patient reported outcomes as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L) and the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 health scale is on a scale of 1 to 7, with 1 being poor health and 7 being excellent health. The EQ-5D-5L scale is on a scale of 0 to 100, with 0 being the worst health one can imagine, and 100 being the best health one can imagine. |
Countries
Austria, France, Germany, Italy, Poland, Spain, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TRC105 + Votrient Weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
TRC105: TRC105 antibody
Votrient: pazopanib | 64 |
| Votrient Standard dose votrient by mouth, once daily
Votrient: pazopanib | 64 |
| Total | 128 |
Baseline characteristics
| Characteristic | Total | TRC105 + Votrient | Votrient |
|---|---|---|---|
| Age, Continuous | 68 years | 69 years | 67 years |
| ECOG Performance Status ECOG Grade 0 | 57 Participants | 30 Participants | 27 Participants |
| ECOG Performance Status ECOG Grade 1 | 68 Participants | 32 Participants | 36 Participants |
| ECOG Performance Status Not Available | 3 Participants | 2 Participants | 1 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 9 Participants | 6 Participants | 3 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 111 Participants | 55 Participants | 56 Participants |
| Race/Ethnicity, Customized Not Reported | 2 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 6 Participants | 2 Participants | 4 Participants |
| Region of Enrollment France | 11 participants | 6 participants | 5 participants |
| Region of Enrollment Poland | 4 participants | 0 participants | 4 participants |
| Region of Enrollment United Kingdom | 17 participants | 8 participants | 9 participants |
| Region of Enrollment United States | 96 participants | 50 participants | 46 participants |
| Sex: Female, Male Female | 77 Participants | 35 Participants | 42 Participants |
| Sex: Female, Male Male | 51 Participants | 29 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 23 / 64 | 20 / 64 |
| other Total, other adverse events | 63 / 63 | 57 / 57 |
| serious Total, serious adverse events | 27 / 63 | 12 / 57 |
Outcome results
Primary
Progression Free Survival of Patients With Unresectable Angiosarcoma
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression free survival is defined as time from randomization to either first disease progression (per independent radiology review of images by RECIST 1.1) or death from any cause.
Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)
Population: All patients randomized onto study by cut off date of interim analysis
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| TRC105 + Votrient | Progression Free Survival of Patients With Unresectable Angiosarcoma | PFS by RECIST 1.1 | 4.2 months |
| TRC105 + Votrient | Progression Free Survival of Patients With Unresectable Angiosarcoma | PFS by Investigator Assessment | 3.5 months |
| Votrient | Progression Free Survival of Patients With Unresectable Angiosarcoma | PFS by RECIST 1.1 | 4.3 months |
| Votrient | Progression Free Survival of Patients With Unresectable Angiosarcoma | PFS by Investigator Assessment | 2.9 months |
Secondary
Objective Response Rate of Patients With Unresectable Angiosarcoma
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Overall response rate is defined as the number of patients with a best response designation of complete response or partial response recorded between the date of randomization and the date of documented progression.
Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)
Population: All patients randomized onto study by cut off date of interim analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TRC105 + Votrient | Objective Response Rate of Patients With Unresectable Angiosarcoma | 3 Participants |
| Votrient | Objective Response Rate of Patients With Unresectable Angiosarcoma | 8 Participants |
Secondary
Overall Survival of Patients With Unresectable Angiosarcoma
Overall survival is the number of death events at 25 months, including all on-study and off-study deaths (past post-treatment 28-day follow up visit)
Time frame: from beginning of study to cut off date of interim analysis (25 months)
Population: All patients randomized onto study by cut off date of interim analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TRC105 + Votrient | Overall Survival of Patients With Unresectable Angiosarcoma | 17 Participants |
| Votrient | Overall Survival of Patients With Unresectable Angiosarcoma | 19 Participants |
Secondary
To Characterize Patient Reported Outcomes Between the Two Arms of the Study
Patient reported outcomes as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L) and the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 health scale is on a scale of 1 to 7, with 1 being poor health and 7 being excellent health. The EQ-5D-5L scale is on a scale of 0 to 100, with 0 being the worst health one can imagine, and 100 being the best health one can imagine.
Time frame: Screening and 9 weeks (Cycle 3 Day 1)
Population: All patients who completed the questionnaire during specified intervals listed below
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| TRC105 + Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EORTC QLQ-C30 Health Score at Screening | 5 units on a scale |
| TRC105 + Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EQ-5D-5L Health Score at Screening | 75 units on a scale |
| TRC105 + Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EORTC QLQ-C30 Health Score at Cycle 3 Day 1 | 4 units on a scale |
| TRC105 + Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EQ-5D-5L Health Score at Cycle 3 Day 1 | 70 units on a scale |
| Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EQ-5D-5L Health Score at Cycle 3 Day 1 | 70 units on a scale |
| Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EORTC QLQ-C30 Health Score at Screening | 5 units on a scale |
| Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EORTC QLQ-C30 Health Score at Cycle 3 Day 1 | 5 units on a scale |
| Votrient | To Characterize Patient Reported Outcomes Between the Two Arms of the Study | EQ-5D-5L Health Score at Screening | 75 units on a scale |